Dublin, June 16, 2022 (GLOBE NEWSWIRE) -- The "Soft Tissue Biologics Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030" report has been added to ResearchAndMarkets.com's offering.
The model discusses in detail the impact of COVID-19 on Soft Tissue Biologics Devices market for the year 2020 and beyond. Orthopedic soft tissue biologics are widely used in procedures where tendon or ligament is torn or damaged in the human body. They are made from substances that are naturally found in the body and can be used in regeneration and repair of the musculoskeletal tissues.
Minimally invasive surgery and arthroscopy has helped in early intervention and treatment of multiple medical conditions and regenerative medicine has facilitated the in-growth, expansion and preservation of the normal tissue.
The orthopedic soft tissue biologics Devices market is primarily driven by procedures performed for anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) reconstruction, rotator cuff repair, and Achilles tendon repair. Other medical conditions where soft tissue biologics are used include: Medial Collateral Ligament repair, Lateral Collateral Ligament repair, Medial Patellofemoral Ligament repair, Ulnar Collateral Ligament repair, flexor tendon and hip flexor repair.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Key Inclusions of the market model are:
Currently marketed Soft Tissue Biologics Devices and evolving competitive landscape:
- Insightful review of the key industry trends
- Annualized total Soft Tissue Biologics Devices market revenue by segment and market outlooks from 2015-2030
- Granular data on total procedures, units, average selling prices and market values by segment
Global, Regional and Country level market specific insights:
- Qualitative market specific information is available with global trends further broken down into regional trends. In addition the publisher's analysts' provide unique country specific insights on the market
- SWOT analysis for Soft Tissue Biologics Devices market
- Competitive dynamics insights and trends provided for Soft Tissue Biologics Devices market
Scope
- CMO executives who must have deep understanding of the Soft Tissue Biologics marketplace to make strategic planning and investment decisions
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Companies covered:
- LifeNet Health Inc
- Surgalign Holdings Inc
- ConMed Corp
- Allosource
- Arthrex Inc
- Smith & Nephew Plc
- Stryker Corp
- Zimmer Biomet Holdings
For more information about this report visit https://www.researchandmarkets.com/r/osm94p
